ANTIBODIES TARGETING FOLLICLE STIMULATING HORMONE FOR USE IN OSTEOPOROSIS TREATMENT AND PREVENTION

A new paradigm for osteoporosis prevention and treatment was described by Dr. Mone Zaidi, Director of the Mount Sinai Bone Program at the Icahn School of Medicine at Mount Sinai.  By blocking follicle-stimulating hormone (FSH) in pre-clinical models of menopause using an antibody against FSH, bone regeneration was enhanced by both slowing of bone destruction and building bone.  Since the antibody is not retained in bone, this is poised to be a safer approach than current treatments.  Further, this approach is anticipated to not just treat an established disease, but to prevent it.

Current Development Status

• Significant in vitro and in vivo data generated using both polyclonal antisera and newly generated monoclonal antibodies

Applications

• Osteoporosis

Advantages

• Antibody is not retained in bone – an undesirable side-effect of many osteoporosis treatments
• Novel target that is key in the earliest stages of osteoporosis

Publications

• Masilamani M, et al. Soybean isoflavones regulate dendritic cell function and suppress allergic sensitization to peanut. J Allergy Clin Immunol. 2011. 128(6):1242-1250

Patent Status

• International Application PCT/US2005/035019 filed September 27, 2005
• Status: Published. International Publication No. WO 2006/039400
• EPC Application EP20050816348 filed September 27, 2005
• Status: Published. EPC Publication No. EP1804824
• Canadian Application CA 2581896 filed September 27, 2005
• Status: Pending
• US Utility Application 11/664,030 filed October 30, 2007
• Status: Issued. US Patent No. 8,435,948

Contact

Jeanne Farrell, PhD
Business Development Director
Mount Sinai Innovation Partners | Icahn School of Medicine at Mount Sinai
Phone: 646.605.7314